The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.
28 companies currently qualify for inclusion, with 15 filing in U.S dollars and 13 in the Canadian currency. Since our last report, we added Cannex Capital (CSE: CNNX) (OTC: CNXXF). We note that two companies likely qualify but can’t be included at this time due to their not providing quarterly data yet, Curaleaf (CSE: CURA) and Elixinol Global (ASX: EXL) (OTC: ELLXF). We expect to be adding several additional companies over the balance of 2018 as existing public companies continue to ramp up sales and as others begin to trade publicly.
MedMen Enterprises (CSE: MMEN) (OTC: MMNFF) was one of two companies reporting financials in U.S. dollars that we updated in October, with the June fiscal year-end quarter results pushing it to second place among companies reporting in U.S. dollars. Sales of $20.6 million grew 1317% and generated an operating loss of $66 million. Cannex Capital reported earlier this month that it generated revenue of $3.4 million in the company’s fiscal Q1 ending July 31st, with adjusted EBITDA of $1.78 million. About 2/3 of the revenue can be attributed to its real estate operations and the balance to supplies.
In November, we will get reports from twelve of the fifteen companies, with six due before mid-month, including CV Sciences (OTC: CVSI), GrowGeneration (OTC: GRWG), Innovative Industrial Properties (NYSE: IIPR), Marimed (OTC: MRMD), Terra Tech (OTC: TRTC) and Tilray (NASDAQ: TLRY), which has provided guidance that its sales will be between $10 million and $10.5 million. We also expect to add Medicine Man Technologies (OTC: MDCL) when it reports, as it has pre-announced sales of at least $4.5 million. KushCo Holdings (OTC: KSHB), which pre-announced its Q4 sales at about $19 million in September, which would represent 120% growth from year-ago sales, is expected to file by the end of November, along with five others, including Charlotte’s Web (CSE: CWEB) (OTC: CWBHF), Golden Leaf Holdings (CSE: GLH) (OTC: GLDFF), Green Thumb Industries (CSE: GTII) (OTC: GTBIF), MedMen, Planet 13 Holdings (CSE: PLTH) (OTC: PLNHF) and Trulieve (CSE: TRUL) (OTC: TCNNF)
Of the companies that report in Canadian dollars, Aphria (TSX: APH) (OTC: APHQF) generated sales of C$13.3 million in its fiscal Q1 ending August 31st, representing growth of 117%. The company encountered operational challenges and saw adjusted gross margins decline to 63.6% as the company reported adjusted EBITDA of -C$4.0 million.
Of the companies that report in Canadian dollars, we will see ten of the thirteen issue financial reports in November. In the first half of the month, we will hear from Aurora Cannabis (TSX: ACB) (NYSE: ACB), CannTrust (TSX: TRST) (OTC: CNTTF), Canopy Growth (TSX: WEED) (NYSE: CGC) and Cronos Group (TSX: CRON) (NASDAQ: CRON). According to Sentieo, Aurora Cannabis is expected to report sales of C$39.5 million 379% growth), CannTrust is expected to report sales of C$13.65 million (122% growth), Canopy Growth is expected to report sales of C$91.2 million (419% growth), and Cronos Group is expected to report sales of C$14.85 million (1034% growth). By month-end, we will hear from 1933 Industries (CSE: TGIF) (OTC: TGIFF), Isodiol International (CSE: ISOL) (OTC: ISOLF), MPX Bioceutical (CSE: MPX) (OTC: MPXEF), Origin House (CSE: OH) (OTC: ORHOF), which was formerly CannaRoyalty, Sunniva (CSE: SNN) (OTC: SNNVF) and Supreme Cannabis (TSXV: FIRE) (OTC: SPRWF).
Visit the Public Cannabis Company Revenue Tracker to track and explore the complete list of qualifying companies.
